Drug Patents owned by Abbvie Inc

1. List of Mavyret drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648037 ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors
Jan, 2032

(8 years from now)

US8937150 ABBVIE INC Anti-viral compounds
May, 2032

(9 years from now)

USRE48923 ABBVIE INC Crystal forms
May, 2035

(12 years from now)

US9321807 ABBVIE INC Crystal forms
Jun, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028937 ABBVIE INC Anti-viral compounds
Jun, 2030

(7 years from now)

US10039754 ABBVIE INC Anti-viral compounds
Jun, 2030

(7 years from now)

US9586978 ABBVIE INC Anti-viral compounds
Nov, 2030

(7 years from now)

US10039754

(Pediatric)

ABBVIE INC Anti-viral compounds
Dec, 2030

(7 years from now)

US10028937

(Pediatric)

ABBVIE INC Anti-viral compounds
Dec, 2030

(7 years from now)

US9586978

(Pediatric)

ABBVIE INC Anti-viral compounds
May, 2031

(8 years from now)

US8648037

(Pediatric)

ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors
Jul, 2032

(9 years from now)

US8937150

(Pediatric)

ABBVIE INC Anti-viral compounds
Nov, 2032

(9 years from now)

US10286029 ABBVIE INC Method for treating HCV
Mar, 2034

(11 years from now)

US11484534 ABBVIE INC Methods for treating HCV
Mar, 2034

(11 years from now)

US10286029

(Pediatric)

ABBVIE INC Method for treating HCV
Sep, 2034

(11 years from now)

US11484534

(Pediatric)

ABBVIE INC Methods for treating HCV
Sep, 2034

(11 years from now)

USRE48923

(Pediatric)

ABBVIE INC Crystal forms
Nov, 2035

(12 years from now)

US9321807

(Pediatric)

ABBVIE INC Crystal forms
Dec, 2035

(12 years from now)

US11246866 ABBVIE INC Solid pharmaceutical compositions for treating HCV
Jun, 2036

(13 years from now)

US11246866

(Pediatric)

ABBVIE INC Solid pharmaceutical compositions for treating HCV
Dec, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 3, 2022
New Patient Population (NPP) Apr 30, 2022
Orphan Drug Exclusivity (ODE) Jun 10, 2028
New Dosing Schedule (D) Sep 26, 2022
M Apr 10, 2023
Pediatric Exclusivity (PED) Feb 3, 2023

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 03 August, 2017

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg

Dosage: TABLET;ORAL

More Information on Dosage

2. List of Oriahnn (copackaged) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2024

(1 year, 5 months from now)

US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11459305 ABBVIE INC Processes for the preparation of uracil derivatives
Nov, 2028

(5 years from now)

US11045470 ABBVIE INC Methods of treating heavy menstrual bleeding
Mar, 2034

(11 years from now)

US10881659 ABBVIE INC Methods of treating heavy menstrual bleeding
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023
New Product (NP) May 29, 2023

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 29 May, 2020

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)

Dosage: CAPSULE;ORAL

More Information on Dosage

3. List of Orilissa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2024

(1 year, 5 months from now)

US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176211 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Jul, 2024

(1 year, 5 months from now)

US11344551 ABBVIE INC Methods of treating heavy menstrual bleeding
Mar, 2034

(11 years from now)

US10537572 ABBVIE INC Methods of administering elagolix
Sep, 2036

(13 years from now)

US10682351 ABBVIE INC Methods of administering elagolix
Sep, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women to reduce dysmenorrhea and non-menstrual pelvic pain; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women having dyspareunia associated with endometriosis; Management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin; Management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole

Dosage: TABLET;ORAL

How can I launch a generic of ORILISSA before it's patent expiration?
More Information on Dosage

4. List of Qulipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9499545 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(8 years from now)

US8754096 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(9 years from now)

US9850246 ABBVIE INC Process for making CGRP receptor antagonists
Mar, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117836 ABBVIE INC Tablet formulation for CGRP active compounds
Jan, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 28, 2026

Drugs and Companies using ATOGEPANT ingredient

NCE-1 date: September, 2025

Market Authorisation Date: 28 September, 2021

Treatment: Preventive treatment of episodic migraine in adults

Dosage: TABLET;ORAL

More Information on Dosage

5. List of Rinvoq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47221 ABBVIE INC Tricyclic compounds
Dec, 2030

(7 years from now)

US8962629 ABBVIE INC Tricyclic compounds
Jan, 2031

(7 years from now)

US9951080 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10981923 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11186584 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10519164 ABBVIE INC Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US9963459 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof
Oct, 2036

(13 years from now)

US10981924 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10344036 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10550126 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10730883 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11198697 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10597400 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11365198 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10202393 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10995095 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11512092 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 14, 2024
New Chemical Entity Exclusivity (NCE) Aug 16, 2024

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, or when use of those therapies are inadvisable; Treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tnf blockers

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

6. List of Technivie drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(6 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(8 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268349 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(1 year, 6 months from now)

US8399015 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(1 year, 6 months from now)

US8268349

(Pediatric)

ABBVIE INC Solid pharmaceutical dosage form
Feb, 2025

(2 years from now)

US8399015

(Pediatric)

ABBVIE INC Solid pharmaceutical dosage form
Feb, 2025

(2 years from now)

US9006387 ABBVIE INC Anti-viral compounds
Jun, 2030

(7 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV
Apr, 2031

(8 years from now)

US8686026 ABBVIE INC Solid compositions
Jun, 2031

(8 years from now)

US8420596

(Pediatric)

ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Oct, 2031

(8 years from now)

Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Market Authorisation Date: 24 July, 2015

Treatment: Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir

Dosage: TABLET;ORAL

More Information on Dosage

7. List of Venclexta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546399 ABBVIE INC Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
Jun, 2031

(8 years from now)

US10730873 ABBVIE INC Salts and crystalline forms of an apoptosis-inducing agent
Nov, 2031

(8 years from now)

US8722657 ABBVIE INC Salts and crystalline forms of an apoptosis-inducing agent
Jan, 2032

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174982 ABBVIE INC Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
May, 2030

(7 years from now)

US11369599 ABBVIE INC Melt-extruded solid dispersions containing an apoptosis-inducing agent
May, 2032

(9 years from now)

US10993942 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(10 years from now)

US11413282 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(10 years from now)

US11110087 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Sep, 2033

(10 years from now)

US9539251 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Sep, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 15, 2026
New Indication (I) May 15, 2022
M Oct 16, 2023

Drugs and Companies using VENETOCLAX ingredient

Market Authorisation Date: 11 April, 2016

Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll); Treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnosed acute myeloid leukemia (aml) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; Treatment of patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for 1 week followed by 100 mg per day for 1 week; Treatment of adults with relapsed, refractory or previously untreated chronic lymphocytic leukemia including a dose ramp-up and in combination with obinutuzumab in multiple 28-day dosing cycles followed by administration in absence of obinutuzumab; Treatment of acute myeloid leukemia (aml) by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine in adults 75 years or older or having certain comorbidities according to a dose ramp-up including a 100 mg per day dose; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic leukemia (sll) in combination with a ga101 antibody such as obinutuzumab for one or more dosing periods, wherein the cll or sll is a cd20-expressing cancer

Dosage: TABLET;ORAL

How can I launch a generic of VENCLEXTA before it's patent expiration?
More Information on Dosage

8. List of Viekira Pak (copackaged) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8501238 ABBVIE INC Anti-infective agents and uses thereof
Dec, 2028

(5 years from now)

US8188104 ABBVIE INC Anti-infective agents and uses thereof
May, 2029

(6 years from now)

US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(6 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(8 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399015 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(1 year, 6 months from now)

US8268349 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(1 year, 6 months from now)

US9139536 ABBVIE INC Anti-infective agents and uses thereof
Nov, 2028

(5 years from now)

US9006387 ABBVIE INC Anti-viral compounds
Jun, 2030

(7 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV
Apr, 2031

(8 years from now)

US8686026 ABBVIE INC Solid compositions
Jun, 2031

(8 years from now)

US8685984 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US8492386 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US8466159 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US8680106 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US9629841 ABBVIE INC Formulations of pyrimidinedione derivative compounds
Oct, 2033

(10 years from now)

US10201542 ABBVIE INC Formulations of pyrimidinedione derivative compounds
Oct, 2033

(10 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.; Use of dasabuvir to inhibit viral replication for the treatment of hcv infection.

Dosage: TABLET;ORAL

More Information on Dosage

9. List of Viekira Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8501238 ABBVIE INC Anti-infective agents and uses thereof
Sep, 2028

(5 years from now)

US8188104 ABBVIE INC Anti-infective agents and uses thereof
May, 2029

(6 years from now)

US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(6 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(8 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399015 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(1 year, 6 months from now)

US8268349 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(1 year, 6 months from now)

US9139536 ABBVIE INC Anti-infective agents and uses thereof
Nov, 2028

(5 years from now)

US9006387 ABBVIE INC Anti-viral compounds
Jun, 2030

(7 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV
Apr, 2031

(8 years from now)

US8686026 ABBVIE INC Solid compositions
Jun, 2031

(8 years from now)

US10201584 ABBVIE INC Compositions and methods for treating HCV
May, 2032

(9 years from now)

US10201541 ABBVIE INC Compositions and methods for treating HCV
May, 2032

(9 years from now)

US8492386 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US8685984 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US8466159 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US8680106 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US10105365 ABBVIE INC Solid antiviral dosage forms
Jan, 2035

(11 years from now)

US9333204 ABBVIE INC Solid antiviral dosage forms
Jan, 2035

(11 years from now)

US9744170 ABBVIE INC Solid antiviral dosage forms
Jan, 2035

(11 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Market Authorisation Date: 22 July, 2016

Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using dasabuvir/ombitasvir/paritaprevir/ritonavir fixed dose combination; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.; Use of dasabuvir to inhibit viral replication for the treatment of hcv infection.

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

10. List of Vuity drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610518 ABBVIE INC Presbyopia treatments
Apr, 2039

(16 years from now)

US11285134 ABBVIE INC Presbyopia treatments
Apr, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Oct 28, 2024

Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 October, 2021

Treatment: Use of vuity for the treatment of presbyopia in adults

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic